Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Oncothyreon Shares Plunge After Lung Cancer Treatment Fails


Biotech company's partner says vaccine didn't meet a study goal to show effectiveness. Stock drops almost 60%.

MINYANVILLE ORIGINAL Shares of Oncothyreon (NASDAQ:ONTY) are plunging after a vaccine the company developed to treat lung cancer failed in a clinical study.

Oncothyreon's partner Merck KGaA (PINK:MKGAY) of Germany, which is testing the vaccine Stimuvax, said the treatment failed to meet its goal of improving overall survival in a pivotal study. The trial included more than 1,500 patients with advanced non-small cell lung cancer, which is the most common form of the disease.

Oncothyreon CEO Robert Kirkman said on a conference call with analysts Wednesday that he was disappointed about the news, but he was unable to provide specific details about the study's outcome. Merck, which licensed the treatment, did not share that information with him, he says.

"These results are disappointing for you, for us and, most especially, for the patients with non-small cell lung cancer who need new therapies," Kirkman told analysts.

The company's stock fell 58% to $1.91 in morning trading Wednesday. The shares have lost three-quarters of their value in 2012.

Investor expectations were very high for Stimuvax at the beginning of this year. In fact, news that key study results for the vaccine probably wouldn't be available until 2013 sent Oncothyreon's shares tumbling in March. At the time, Kirkman said that he was still encouraged that the trial wasn't stopped because of lack of effectiveness. He called Stimuvax a potentially "game-changing product" for lung cancer. (See Oncothyreon's Stock Tanks on Delay of Cancer Drug Study Results.) The product was designed to enable a patient's immune system to fight cancer.

Merck said it would review Stimuvax's effects on some patient subgroups in the trial but provided no specifics. Study data will be presented at upcoming scientific meetings, which likely will include the annual meeting of the American Society of Clinical Oncology in the spring.

Kirkman says he expects Oncothyreon will end this year with about $80 million in cash and short-term investments. That would fund roughly two years of operations using the company's current burn rate, he says. The company will provide more financial guidance in March when it announces fourth-quarter results, Kirkman says.

Moving past Stimuvax's flop, investors who stick with the stock will focus on another cancer treatment, PX-866, says Cowen & Co. analyst Simos Simeonidis.

PX-866 is an oral treatment being studied in combination with older cancer drugs and by itself. Simeonidis says he expects some study data for this drug to be revealed early next year.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos